{
    "symbol": "EYEN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 21:52:04",
    "content": " Just a few weeks ago, we announced positive results from VISION-2 which is our second phase three study of MicroLine and a modified per protocol analysis of the valuable patients excluding a non study related adverse events impacting pupil size or reactivity, otherwise known as new onset anisocoria. To-date our license agreement have generated approximately $16 million in license fees, and we have the potential to earn an additional 60 million in net license and development milestones, as well as reimbursable expenses over the next four years."
}